PubRank

Drew M Pardoll

Author PubWeight™ 292.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 52.99
2 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 35.24
3 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010 17.13
4 Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012 13.12
5 PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015 13.08
6 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014 9.86
7 A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009 7.45
8 Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012 7.26
9 Cancer immunotherapy comes of age. J Clin Oncol 2011 5.87
10 Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002 5.78
11 Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007 5.65
12 Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011 5.63
13 Mechanisms of immune evasion by tumors. Adv Immunol 2006 5.34
14 IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009 5.05
15 Role of LAG-3 in regulatory T cells. Immunity 2004 4.36
16 Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007 4.29
17 Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2011 3.81
18 Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009 3.71
19 Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2012 3.68
20 Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006 3.49
21 Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 2003 3.12
22 Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 2007 3.00
23 Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004 3.00
24 Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood 2007 2.93
25 Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013 2.81
26 In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009 2.76
27 Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 2009 2.76
28 LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest 2007 2.57
29 Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005 2.37
30 In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med 2005 2.28
31 An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity 2013 1.98
32 High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 2008 1.79
33 Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol 2002 1.70
34 Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med 2002 1.68
35 A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol 2010 1.65
36 Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity 2012 1.61
37 Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009 1.60
38 Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol 2005 1.56
39 Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol 2009 1.54
40 Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis 2010 1.53
41 Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009 1.51
42 Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun 2003 1.49
43 Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014 1.47
44 Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 2013 1.47
45 IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 2010 1.45
46 LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol 2009 1.33
47 B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem Biophys Res Commun 2007 1.29
48 Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A 2007 1.28
49 Cellular vaccine approaches. Cancer J 2010 1.27
50 Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res 2006 1.25
51 Retracted Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. J Immunol 2003 1.21
52 Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin. Nature 2007 1.21
53 Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. J Clin Invest 2006 1.20
54 CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction. J Immunol 2003 1.19
55 Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol 2003 1.18
56 Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 2008 1.17
57 Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci U S A 2005 1.14
58 Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2002 1.10
59 Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther 2003 1.09
60 Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst 2011 1.09
61 Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res 2007 1.08
62 Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol 2009 1.07
63 Integrin alpha2 mediates selective metastasis to the liver. Cancer Res 2009 1.03
64 Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells. Nat Med 2003 1.00
65 Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. J Immunol Methods 2002 1.00
66 Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol 2008 0.99
67 Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res 2005 0.98
68 Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004 0.97
69 AACR Cancer Progress Report 2013. Clin Cancer Res 2013 0.95
70 Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res 2006 0.94
71 Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med 2013 0.93
72 Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther 2005 0.92
73 Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction. Aging Cell 2011 0.90
74 PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neurooncol 2014 0.87
75 Immunologic consequences of signal transducers and activators of transcription 3 activation in human squamous cell carcinoma. Cancer Res 2010 0.87
76 Inhibition of vasospasm with lymphocyte function-associated antigen-1 monoclonal antibody in a femoral artery model in rats. J Neurosurg 2002 0.87
77 Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood 2002 0.86
78 Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor. Cancer Immunol Immunother 2002 0.84
79 Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens. Int J Cancer 2005 0.82
80 Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines. Int J Cancer 2002 0.82
81 Tumor immunology--towards a paradigm of reciprocal research. Semin Cancer Biol 2002 0.82
82 Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. Int J Radiat Oncol Biol Phys 2013 0.81
83 The role of STAT3 activation in modulating the immune microenvironment of GBM. J Neurooncol 2012 0.81
84 Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. Prostate 2011 0.81
85 Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J Neurooncol 2004 0.80
86 Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2016 0.80
87 Shift from pStat6 to pStat3 predominance is associated with inflammatory bowel disease-associated dysplasia. Inflamm Bowel Dis 2011 0.78
88 Advances in gene therapy for malignant melanoma. Cancer Control 2002 0.77
89 Concepts of immunotherapy for glioma. J Neurooncol 2015 0.77
90 Hypoxia-inducible factor 1: A link between metabolism and T cell differentiation and a potential therapeutic target. Oncoimmunology 2012 0.77
91 Tumor reactive T cells get a boost. Nat Biotechnol 2002 0.76
92 Glycolipid antigens for treating hepatic colorectal cancer metastases and their effect on the therapeutic efficacy of live attenuated Listeria monocytogenes. Arch Surg 2012 0.75
93 Building the bionic T cell. Nat Med 2007 0.75
94 Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 2017 0.75
95 Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2. J Neurooncol 2003 0.75